$PCRX
Pacira Biosciences Inc Stock $pcrx

$pcrx Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000139681423000010 Filed on February 28, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$160.3M	$172.0M	$666.8M
YoY Change	1.49%	8.02%	23.14%
Cost Of Revenue	$49.02M	$61.92M	$199.3M
YoY Change	35.89%	58.73%	42.09%
Gross Profit	$111.3M	$110.0M	$467.5M
YoY Change	-8.69%	-8.44%	16.51%
Gross Profit Margin	69.43%	63.99%	70.11%
Selling, General & Admin	$70.84M	$63.97M	$254.5M
YoY Change	10.24%	24.93%	27.68%
% of Gross Profit	63.64%	58.13%	54.44%
Research & Development	$17.14M	$17.51M	$84.80M
YoY Change	-20.67%	12.83%	52.66%
% of Gross Profit	15.4%	15.91%	18.14%
Depreciation & Amortization	$19.60M	$30.41M	$91.50M
YoY Change	-2.15%	132.64%	220.52%
% of Gross Profit	17.61%	27.63%	19.57%
Operating Expenses	$87.98M	$95.80M	$339.3M
YoY Change	2.47%	28.81%	33.12%
Operating Profit	-$3.091M	$14.24M	$60.02M
YoY Change	-117.77%	-68.92%	-33.25%
Interest Expense	$9.589M	-$8.256M	$39.98M
YoY Change	-6.41%	-20.18%	25.91%
% of Operating Profit		-57.97%	66.6%
Other Income/Expense, Net	-$23.38M	$81.00K	-$46.72M
YoY Change	131.54%	-222.73%	39.39%
Pretax Income	-$26.47M	-$18.07M	$13.30M
YoY Change	-462.96%	191.51%	-76.42%
Income Tax	-$6.938M	-$7.966M	-$2.607M
% Of Pretax Income			-19.6%
Net Earnings	-$19.54M	-$10.10M	$15.91M
YoY Change	-386.12%	96.92%	-62.1%
Net Earnings / Revenue	-12.18%	-5.87%	2.39%
Basic Earnings Per Share	-$0.43		$0.35
Diluted Earnings Per Share	-$0.43	-$0.22	$0.34
COMMON SHARES
Basic Shares Outstanding	45.95M shares	45.88M shares	45.52M shares
Diluted Shares Outstanding	45.95M shares		46.54M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$174.0M	$288.7M	$288.7M
YoY Change	-61.52%	-56.03%	-56.03%
Cash & Equivalents	$35.55M	$104.1M	$104.1M
Short-Term Investments	$138.5M	$184.5M	$184.5M
Other Short-Term Assets	$15.93M	$15.22M	$15.22M
YoY Change	-16.4%	3.06%	3.06%
Inventory	$92.98M	$96.06M	$96.06M
Prepaid Expenses
Receivables	$93.21M	$98.40M	$98.40M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$376.1M	$498.3M	$498.3M
YoY Change	-43.61%	-42.46%	-42.46%
LONG-TERM ASSETS
Property, Plant & Equipment	$181.6M	$183.5M	$254.4M
YoY Change	-4.29%	-2.59%	-3.94%
Goodwill	$163.2M	$163.2M
YoY Change	12.01%	12.43%
Intangibles	$526.2M	$540.5M
YoY Change	-13.68%	-13.37%
Long-Term Investments	$40.57M	$64.38M	$64.38M
YoY Change	13.41%	192.8%	192.8%
Other Assets	$167.6M	$160.3M	$160.3M
YoY Change	-1.01%	4.53%	4.53%
Total Long-Term Assets	$1.147B	$1.183B	$1.183B
YoY Change	-6.3%	-2.19%	-2.19%
TOTAL ASSETS
Total Short-Term Assets	$376.1M	$498.3M	$498.3M
Total Long-Term Assets	$1.147B	$1.183B	$1.183B
Total Assets	$1.523B	$1.681B	$1.681B
YoY Change	-19.46%	-18.99%	-18.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$17.26M	$15.22M	$15.22M
YoY Change	16.29%	44.36%	44.36%
Accrued Expenses	$61.63M	$89.79M	$91.61M
YoY Change	-29.7%	-29.61%	-27.58%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$10.85M	$33.65M	$33.65M
YoY Change	-94.4%	-91.02%	-91.02%
Total Short-Term Liabilities	$98.70M	$147.8M	$147.8M
YoY Change	-67.65%	-71.64%	-71.64%
LONG-TERM LIABILITIES
Long-Term Debt	$542.9M	$655.8M	$655.8M
YoY Change	-25.6%	-2.77%	-2.77%
Other Long-Term Liabilities	$11.58M	$9.669M	$102.6M
YoY Change	7.99%	-51.59%	-31.28%
Total Long-Term Liabilities	$11.58M	$9.669M	$758.4M
YoY Change	7.99%	-51.59%	-7.94%
TOTAL LIABILITIES
Total Short-Term Liabilities	$98.70M	$147.8M	$147.8M
Total Long-Term Liabilities	$11.58M	$9.669M	$758.4M
Total Liabilities	$755.4M	$906.2M	$906.2M
YoY Change	-36.09%	-32.62%	-32.62%
SHAREHOLDERS EQUITY
Retained Earnings	-$168.3M	-$148.8M
YoY Change	6.62%	-29.8%
Common Stock	$46.00K	$46.00K
YoY Change	2.22%	2.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$768.0M	$775.0M	$775.0M
YoY Change
Total Liabilities & Shareholders Equity	$1.523B	$1.681B	$1.681B
YoY Change	-19.46%	-18.99%	-18.99%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$19.54M	-$10.10M	$15.91M
YoY Change	-386.12%	96.92%	-62.1%
Depreciation, Depletion And Amortization	$19.60M	$30.41M	$91.50M
YoY Change	-2.15%	132.64%	220.52%
Cash From Operating Activities	$19.13M	$42.04M	$145.3M
YoY Change	-37.85%	81.08%	15.56%
INVESTING ACTIVITIES
Capital Expenditures	$6.565M	$5.492M	$30.08M
YoY Change	-14.38%	-159.92%	-34.43%
Acquisitions			$0.00
YoY Change
Other Investing Activities	$72.75M	$16.68M	-$195.1M
YoY Change	-136.31%	-78.08%	-878.07%
Cash From Investing Activities	$66.18M	$11.19M	-$225.2M
YoY Change	-131.82%	-83.28%	983.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$153.9M	-58.51M	-$401.5M
YoY Change	-15.24%	-116.19%	-205.47%
NET CHANGE
Cash From Operating Activities	$19.13M	42.04M	$145.3M
Cash From Investing Activities	$66.18M	11.19M	-$225.2M
Cash From Financing Activities	-$153.9M	-58.51M	-$401.5M
Net Change In Cash	-$68.59M	-5.285M	-$481.4M
YoY Change	-80.88%	-101.17%	-199.14%
FREE CASH FLOW
Cash From Operating Activities	$19.13M	$42.04M	$145.3M
Capital Expenditures	$6.565M	$5.492M	$30.08M
Free Cash Flow	$12.56M	$36.55M	$115.2M
YoY Change	-45.64%	12.86%	44.27%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001396814
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member
CY2022	pcrx	Employee Stock Purchase Plan Offering Period EmployeeStockPurchasePlanOfferingPeriod	P6M
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022	dei	Entity File Number EntityFileNumber	001-35060
CY2022	dei	Entity Registrant Name EntityRegistrantName	PACIRA BIOSCIENCES, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	51-0619477
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	5401 West Kennedy Boulevard, Suite 890
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Tampa,
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33609
CY2022	dei	City Area Code CityAreaCode	(813)
CY2022	dei	Local Phone Number LocalPhoneNumber	553-6680
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2022	dei	Trading Symbol TradingSymbol	PCRX
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Small Business EntitySmallBusiness	false
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	1900000000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	45952450	shares
CY2022	dei	Auditor Name AuditorName	KPMG LLP
CY2022	dei	Auditor Location AuditorLocation	Short Hills, NJ
CY2022	dei	Auditor Firm AuditorFirmId	185
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	104139000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	585578000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	184512000	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	70831000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	98397000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	96318000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	96063000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	98550000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15223000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14771000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	498334000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	866048000	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	37209000	usd
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	0	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	183512000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	188401000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	70877000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	76410000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	163243000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	145175000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	540546000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	623968000	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	160309000	usd
CY2021Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	153364000	usd
CY2022Q4	pcrx	Equity Method Investments And Other Assets EquityMethodInvestmentsAndOtherAssets	27170000	usd
CY2021Q4	pcrx	Equity Method Investments And Other Assets EquityMethodInvestmentsAndOtherAssets	21987000	usd
CY2022Q4	us-gaap	Assets Assets	1681200000	usd
CY2021Q4	us-gaap	Assets Assets	2075353000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	15220000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10543000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	89785000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	127555000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	9121000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7891000	usd
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	0	usd
CY2021Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	350466000	usd
CY2022Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	33648000	usd
CY2021Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	24234000	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	0	usd
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	429000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	147774000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	521118000	usd
CY2022Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	404767000	usd
CY2021Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	339267000	usd
CY2022Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	251056000	usd
CY2021Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	335263000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	64802000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	71727000	usd
CY2022Q4	pcrx	Contingent Consideration Noncurrent ContingentConsiderationNoncurrent	28122000	usd
CY2021Q4	pcrx	Contingent Consideration Noncurrent ContingentConsiderationNoncurrent	57598000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9669000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	19972000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	906190000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	1344945000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	730408000	usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	45927790	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	45927790	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	44734308	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44734308	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	46000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	45000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	924095000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	942091000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-148751000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-211895000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-380000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	167000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	775010000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1681200000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2075353000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	666823000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	541533000	usd
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	429647000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	199295000	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	140255000	usd
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	117328000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	84797000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	55545000	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	59421000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	254516000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	199345000	usd
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	193516000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	57288000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	13553000	usd
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	7866000	usd
CY2022	pcrx	Acquisition Related Gain Loss Impairment And Other Net AcquisitionRelatedGainLossImpairmentAndOtherNet	-10903000	usd
CY2021	pcrx	Acquisition Related Gain Loss Impairment And Other Net AcquisitionRelatedGainLossImpairmentAndOtherNet	-42911000	usd
CY2020	pcrx	Acquisition Related Gain Loss Impairment And Other Net AcquisitionRelatedGainLossImpairmentAndOtherNet	-5166000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	606799000	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	451609000	usd
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	383297000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	60024000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	89924000	usd
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	46350000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	4542000	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	896000	usd
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	4629000	usd
CY2022	us-gaap	Interest Expense InterestExpense	39976000	usd
CY2021	us-gaap	Interest Expense InterestExpense	31750000	usd
CY2020	us-gaap	Interest Expense InterestExpense	25671000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-8071000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-11288000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2666000	usd
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2852000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-46722000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-33520000	usd
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-26261000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	13302000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	56404000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	20089000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2607000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	14424000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-125434000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	15909000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	41980000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	145523000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.35
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.95
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.41
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.34
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.92
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.33
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45521000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44262000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42671000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46538000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45630000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43682000	shares
CY2022	us-gaap	Net Income Loss NetIncomeLoss	15909000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	41980000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	145523000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-662000	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-180000	usd
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-3000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	115000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	29000	usd
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-547000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-151000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-4000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	15362000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	41829000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	145519000	usd
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	354944000	usd
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	45229000	usd
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2546000	usd
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	39920000	usd
CY2020	pcrx	Deferred Tax Expense Associated To The Equity Component Of Convertible Debt DeferredTaxExpenseAssociatedToTheEquityComponentOfConvertibleDebt	20450000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-4000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	145523000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	619688000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	23834000	usd
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2811000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	42246000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-151000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	41980000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	730408000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	24387000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2954000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	48092000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-547000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	15909000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	775010000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	15909000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	41980000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	145523000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-7945000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	10872000	usd
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-126613000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	91501000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	28548000	usd
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	19908000	usd
CY2022	pcrx	Amortization Of Other Assets And Unfavorable Lease Obligation AmortizationOfOtherAssetsAndUnfavorableLeaseObligation	4400000	usd
CY2021	pcrx	Amortization Of Other Assets And Unfavorable Lease Obligation AmortizationOfOtherAssetsAndUnfavorableLeaseObligation	2754000	usd
CY2020	pcrx	Amortization Of Other Assets And Unfavorable Lease Obligation AmortizationOfOtherAssetsAndUnfavorableLeaseObligation	2156000	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2807000	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	23152000	usd
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	18254000	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-193000	usd
CY2021	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	10000	usd
CY2020	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-22000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-8071000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	48092000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	42246000	usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	39920000	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-29476000	usd
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-989000	usd
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	5204000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	26134000	usd
CY2021	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	usd
CY2020	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	usd
CY2022	us-gaap	Equity Method Investment Other Than Temporary Impairment EquityMethodInvestmentOtherThanTemporaryImpairment	10000000	usd
CY2021	us-gaap	Equity Method Investment Other Than Temporary Impairment EquityMethodInvestmentOtherThanTemporaryImpairment	0	usd
CY2020	us-gaap	Equity Method Investment Other Than Temporary Impairment EquityMethodInvestmentOtherThanTemporaryImpairment	0	usd
CY2022	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	92000	usd
CY2021	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	2673000	usd
CY2020	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-1618000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2079000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10434000	usd
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5516000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2486000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4467000	usd
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6353000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2699000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1142000	usd
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	739000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	6272000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-10262000	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3312000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-19857000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	5451000	usd
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-5999000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-556000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-104000	usd
CY2020	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-2467000	usd
CY2022	us-gaap	Payment For Contingent Consideration Liability Operating Activities PaymentForContingentConsiderationLiabilityOperatingActivities	0	usd
CY2021	us-gaap	Payment For Contingent Consideration Liability Operating Activities PaymentForContingentConsiderationLiabilityOperatingActivities	6835000	usd
CY2020	us-gaap	Payment For Contingent Consideration Liability Operating Activities PaymentForContingentConsiderationLiabilityOperatingActivities	9409000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	145274000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	125717000	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	77032000	usd
CY2022	us-gaap	Payments To Acquire Business Two Net Of Cash Acquired PaymentsToAcquireBusinessTwoNetOfCashAcquired	0	usd
CY2021	us-gaap	Payments To Acquire Business Two Net Of Cash Acquired PaymentsToAcquireBusinessTwoNetOfCashAcquired	420042000	usd
CY2020	us-gaap	Payments To Acquire Business Two Net Of Cash Acquired PaymentsToAcquireBusinessTwoNetOfCashAcquired	0	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	30076000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	45866000	usd
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	37801000	usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	387685000	usd
CY2021	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	611488000	usd
CY2020	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	546516000	usd
CY2022	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	237576000	usd
CY2021	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	1068736000	usd
CY2020	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	307870000	usd
CY2022	pcrx	Payment Of Contingent Consideration PaymentOfContingentConsideration	32000000	usd
CY2021	pcrx	Payment Of Contingent Consideration PaymentOfContingentConsideration	4000000	usd
CY2020	pcrx	Payment Of Contingent Consideration PaymentOfContingentConsideration	0	usd
CY2022	us-gaap	Proceeds From Sale Of Longterm Investments ProceedsFromSaleOfLongtermInvestments	0	usd
CY2021	us-gaap	Proceeds From Sale Of Longterm Investments ProceedsFromSaleOfLongtermInvestments	9057000	usd
CY2020	us-gaap	Proceeds From Sale Of Longterm Investments ProceedsFromSaleOfLongtermInvestments	0	usd
CY2022	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	13000000	usd
CY2021	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	17187000	usd
CY2020	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	1160000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-225185000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-20790000	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-277607000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	24387000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	23844000	usd
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	45218000	usd
CY2022	pcrx	Proceeds From Shares Issued Under Employee Stock Purchase Plan ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan	2954000	usd
CY2021	pcrx	Proceeds From Shares Issued Under Employee Stock Purchase Plan ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan	2811000	usd
CY2020	pcrx	Proceeds From Shares Issued Under Employee Stock Purchase Plan ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan	2546000	usd
CY2022	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	usd
CY2021	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	363750000	usd
CY2020	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	usd
CY2022	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	78125000	usd
CY2021	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	0	usd
CY2020	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	0	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	1175000	usd
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	4546000	usd
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	12487000	usd
CY2022	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	usd
CY2021	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	5165000	usd
CY2020	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	5591000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-401528000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	380694000	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	222304000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-481439000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	485621000	usd
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	21729000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	585578000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	99957000	usd
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	78228000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	104139000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	585578000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	99957000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	33295000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	6996000	usd
CY2020	us-gaap	Interest Paid Net InterestPaidNet	7205000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	7398000	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	3221000	usd
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	2417000	usd
CY2022	pcrx	Debt Conversion Converted Instrument Shares Issued Value DebtConversionConvertedInstrumentSharesIssuedValue	3040000	usd
CY2021	pcrx	Debt Conversion Converted Instrument Shares Issued Value DebtConversionConvertedInstrumentSharesIssuedValue	0	usd
CY2020	pcrx	Debt Conversion Converted Instrument Shares Issued Value DebtConversionConvertedInstrumentSharesIssuedValue	0	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	5888000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	6828000	usd
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	9288000	usd
CY2022	pcrx	Increase Decrease In Contingent Consideration IncreaseDecreaseInContingentConsideration	0	usd
CY2021	pcrx	Increase Decrease In Contingent Consideration IncreaseDecreaseInContingentConsideration	45241000	usd
CY2020	pcrx	Increase Decrease In Contingent Consideration IncreaseDecreaseInContingentConsideration	0	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:8pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and contingent liabilities, at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used for, among other things, revenue recognition, purchase price allocation, stock-based compensation, inventory costs, impairments of equity investments, long-lived assets, goodwill and other intangible assets, liabilities and accruals, including contingent consideration, and the valuation of deferred tax assets. The Company’s critical accounting estimates are those that are both most important to the Company’s consolidated financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of the uncertainty of factors surrounding the </span></div>estimates or judgments used in the preparation of the consolidated financial statements, actual results could differ from these estimates.
CY2022Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	42600000	usd
CY2021Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	223000000	usd
CY2021Q4	us-gaap	Commercial Paper At Carrying Value CommercialPaperAtCarryingValue	19000000	usd
CY2021Q4	us-gaap	Asset Backed Securities At Carrying Value AssetBackedSecuritiesAtCarryingValue	2600000	usd
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2019Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	4804000	usd
CY2020	us-gaap	Valuation Allowances And Reserves Adjustments ValuationAllowancesAndReservesAdjustments	28117000	usd
CY2020	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	28123000	usd
CY2020Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	4798000	usd
CY2021	us-gaap	Valuation Allowances And Reserves Adjustments ValuationAllowancesAndReservesAdjustments	41835000	usd
CY2021	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	34203000	usd
CY2021Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	12430000	usd
CY2022	us-gaap	Valuation Allowances And Reserves Adjustments ValuationAllowancesAndReservesAdjustments	79932000	usd
CY2022	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	80053000	usd
CY2022Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	12309000	usd
	pcrx	Business Combination Provisional Information Initial Accounting Incomplete Adjustment Deferred Tax Assets BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxAssets	-16906000	usd
	pcrx	Business Combination Provisional Information Initial Accounting Incomplete Adjustment Assets BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssets	-16906000	usd
	pcrx	Business Combination Provisional Information Initial Accounting Incomplete Adjustment Accrued Expenses BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenses	1162000	usd
	pcrx	Business Combination Provisional Information Initial Accounting Incomplete Adjustment Liabilities BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilities	1162000	usd
	pcrx	Business Combination Provisional Information Initial Accounting Incomplete Adjustment Net Assets BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssets	-18068000	usd
	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	18068000	usd
	us-gaap	Business Combination Provisional Information Initial Accounting Incomplete Adjustment Consideration Transferred BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred	0	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	39810000	usd
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	36337000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	28853000	usd
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	35182000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	27400000	usd
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	27031000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	96063000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	98550000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	300992000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	273641000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	117480000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	85240000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	183512000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	188401000	usd
CY2022	us-gaap	Depreciation Depreciation	34200000	usd
CY2021	us-gaap	Depreciation Depreciation	15000000	usd
CY2020	us-gaap	Depreciation Depreciation	12000000	usd
CY2022	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	4100000	usd
CY2021	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	3900000	usd
CY2020	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	2400000	usd
CY2022Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	3300000	usd
CY2021Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	2400000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	13949000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	11976000	usd
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	10055000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	1988000	usd
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	1722000	usd
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	2096000	usd
CY2022	us-gaap	Sublease Income SubleaseIncome	253000	usd
CY2021	us-gaap	Sublease Income SubleaseIncome	0	usd
CY2020	us-gaap	Sublease Income SubleaseIncome	0	usd
CY2022	us-gaap	Lease Cost LeaseCost	15684000	usd
CY2021	us-gaap	Lease Cost LeaseCost	13698000	usd
CY2020	us-gaap	Lease Cost LeaseCost	12151000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	14357000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	12709000	usd
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	14347000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3324000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	8692000	usd
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	42191000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y9M29D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y9M7D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0705
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0696
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	14022000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	13928000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	13078000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	12814000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	12586000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	27350000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	93778000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	19855000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	27122000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	73923000	usd
CY2020Q4	us-gaap	Goodwill Goodwill	99547000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	145175000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	163243000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	590090000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	84410000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	505680000	usd
CY2022Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	624956000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	84410000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	540546000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	590090000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	562968000	usd
CY2021Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	651090000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	27122000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	623968000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	57300000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	13600000	usd
CY2022Q4	pcrx	Finite Lived Intangible Assets Amortization Expense Annual Amount Period1 FiniteLivedIntangibleAssetsAmortizationExpenseAnnualAmountPeriod1	57300000	usd
CY2022Q4	pcrx	Finite Lived Intangible Assets Amortization Expense Annual Amount Period2 FiniteLivedIntangibleAssetsAmortizationExpenseAnnualAmountPeriod2	37400000	usd
CY2022Q4	pcrx	Finite Lived Intangible Assets Amortization Expense Annual Amount Period3 FiniteLivedIntangibleAssetsAmortizationExpenseAnnualAmountPeriod3	7900000	usd
CY2022Q4	pcrx	Finite Lived Intangible Assets Amortization Expense Annual Amount Period4 FiniteLivedIntangibleAssetsAmortizationExpenseAnnualAmountPeriod4	2200000	usd
CY2022	pcrx	Impairment Of Intangible Assets Carrying Value ImpairmentOfIntangibleAssetsCarryingValue	60000000	usd
CY2022	pcrx	Impairment Of Intangible Assets Fair Value ImpairmentOfIntangibleAssetsFairValue	33900000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	26100000	usd
CY2022Q4	pcrx	Accruedsellinggeneralandadministrativeexpenses Accruedsellinggeneralandadministrativeexpenses	11927000	usd
CY2021Q4	pcrx	Accruedsellinggeneralandadministrativeexpenses Accruedsellinggeneralandadministrativeexpenses	12063000	usd
CY2021Q4	pcrx	Accrued Severance Current AccruedSeveranceCurrent	18400000	usd
CY2022Q4	pcrx	Accruedresearchanddevelopmentexpenses Accruedresearchanddevelopmentexpenses	4065000	usd
CY2021Q4	pcrx	Accruedresearchanddevelopmentexpenses Accruedresearchanddevelopmentexpenses	5480000	usd
CY2022Q4	pcrx	Accrued Operating Expenses Current AccruedOperatingExpensesCurrent	14959000	usd
CY2021Q4	pcrx	Accrued Operating Expenses Current AccruedOperatingExpensesCurrent	14912000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	26198000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	45491000	usd
CY2022Q4	pcrx	Accrued Termination Fee Current AccruedTerminationFeeCurrent	13000000	usd
CY2021Q4	pcrx	Accrued Termination Fee Current AccruedTerminationFeeCurrent	0	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	3400000	usd
CY2021Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	35298000	usd
CY2022Q4	pcrx	Accrued End Of Term Fee Current AccruedEndOfTermFeeCurrent	8941000	usd
CY2021Q4	pcrx	Accrued End Of Term Fee Current AccruedEndOfTermFeeCurrent	5358000	usd
CY2022Q4	pcrx	Product Returns Rebatesand Other Fees ProductReturnsRebatesandOtherFees	7295000	usd
CY2021Q4	pcrx	Product Returns Rebatesand Other Fees ProductReturnsRebatesandOtherFees	8953000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	89785000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	127555000	usd
CY2022	pcrx	Settlement Period Convertible Debt Conversion Request SettlementPeriodConvertibleDebtConversionRequest	P40D
CY2022	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	36880000	usd
CY2021	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	9759000	usd
CY2020	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	7650000	usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	4400000	usd
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	2754000	usd
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	2156000	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2807000	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	23152000	usd
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	18254000	usd
CY2022	us-gaap	Interest Costs Capitalized Adjustment InterestCostsCapitalizedAdjustment	4111000	usd
CY2021	us-gaap	Interest Costs Capitalized Adjustment InterestCostsCapitalizedAdjustment	3915000	usd
CY2020	us-gaap	Interest Costs Capitalized Adjustment InterestCostsCapitalizedAdjustment	2389000	usd
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	39976000	usd
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	31750000	usd
CY2020	us-gaap	Interest Expense Debt InterestExpenseDebt	25671000	usd
CY2022	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0547
CY2021	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0666
CY2020	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0715
CY2022Q4	us-gaap	Share Price SharePrice	38.61
CY2022Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	71.78
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	12802000	usd
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases	17187000	usd
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales	-11642000	usd
CY2021	pcrx	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Foreign Currency Gain Loss FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetForeignCurrencyGainLoss	-88000	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	18259000	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases	13000000	usd
CY2022	pcrx	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Impairments FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetImpairments	10000000	usd
CY2022	pcrx	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Foreign Currency Gain Loss FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetForeignCurrencyGainLoss	-67000	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	21192000	usd
CY2022	pcrx	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Impairments FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetImpairments	10000000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	222515000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	25000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	819000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	221721000	usd
CY2022Q4	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	800000	usd
CY2021Q4	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	100000	usd
CY2022	pcrx	Number Of Major Customers NumberOfMajorCustomers	3	customer
CY2021	pcrx	Number Of Major Customers NumberOfMajorCustomers	4	customer
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	45927790	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	45927790	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44734308	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	44734308	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	200000	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	100000	usd
CY2021Q2	pcrx	Sharebased Compensation Arrangementby Sharebased Payment Award Increase In Numberof Shares Authorized SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized	1500000	shares
CY2022Q2	pcrx	Employee Stock Purchase Plans Shares Amount Authorized To Be Sold During Period Increase EmployeeStockPurchasePlansSharesAmountAuthorizedToBeSoldDuringPeriodIncrease	500000	shares
CY2022Q2	pcrx	Employee Stock Purchase Plans Shares Amount Authorized To Be Sold During Period Increase EmployeeStockPurchasePlansSharesAmountAuthorizedToBeSoldDuringPeriodIncrease	500000	shares
CY2022Q4	pcrx	Employee Stock Purchase Plan Espp Sharesin Espp EmployeeStockPurchasePlanESPPSharesinESPP	1000000	shares
CY2022Q4	pcrx	Maximum Fair Market Value Purchaseof Espp Shares MaximumFairMarketValuePurchaseofESPPShares	25000	usd
CY2022Q4	pcrx	Employee Stock Purchase Planfairvalue EmployeeStockPurchasePlanfairvalue	0.85
CY2022	pcrx	Stock Purchased And Issued During Period Shares Employee Stock Purchase Plans StockPurchasedAndIssuedDuringPeriodSharesEmployeeStockPurchasePlans	71301	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	14606701	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	13894661	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	712040	shares
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	48092000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	42246000	usd
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	39920000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	48092000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	42246000	usd
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	39920000	usd
CY2022	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	10219000	usd
CY2021	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	8989000	usd
CY2020	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	8578000	usd
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6706378	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	42.80
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y18D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	50652000	usd
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1502803	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	47.50
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1428111	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	31.67
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	34227000	usd
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	426925	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	42.08
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	119027	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	71.71
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6235118	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	45.98
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y11M19D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	102955000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	890277	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	60.27
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	732117	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	32.56
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	23967000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	278233	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	46.46
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	64505	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	80.31
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6050540	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	49.32
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y7M2D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	81407000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1061630	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	59.99
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	689464	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	35.37
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	23983000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	113506	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	54.97
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	36206	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	79.90
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6272994	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	52.38
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y3M10D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2011000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4224921	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	50.51
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y2M1D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1997000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	6272994	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	52.38
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y3M10D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	2011000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	15909000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	41980000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	145523000	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45521000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44262000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42671000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46538000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45630000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43682000	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.35
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.95
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.41
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.34
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.92
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.33
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9451000	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2270000	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4352000	shares
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	21068000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	64751000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	17000000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-7766000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-8347000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	3089000	usd
CY2022	pcrx	Income Lossfrom Continuing Operationsbefore Income Taxes Total IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal	13302000	usd
CY2021	pcrx	Income Lossfrom Continuing Operationsbefore Income Taxes Total IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal	56404000	usd
CY2020	pcrx	Income Lossfrom Continuing Operationsbefore Income Taxes Total IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal	20089000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-6000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	5309000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	3533000	usd
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1185000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	29000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	19000	usd
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	5338000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3552000	usd
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1179000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-2781000	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	12554000	usd
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-99164000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-5164000	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1682000	usd
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-27449000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-7945000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	10872000	usd
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-126613000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2607000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	14424000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-125434000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	2793000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	11845000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	4219000	usd
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-448000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0337
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	2154000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0382
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	632000	usd
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0315
CY2022	pcrx	Effective Income Tax Rate Reconciliation Foreign Amount EffectiveIncomeTaxRateReconciliationForeignAmount	248000	usd
CY2022	pcrx	Effective Income Tax Rate Reconciliation Foreign EffectiveIncomeTaxRateReconciliationForeign	0.0186
CY2021	pcrx	Effective Income Tax Rate Reconciliation Foreign Amount EffectiveIncomeTaxRateReconciliationForeignAmount	-651000	usd
CY2021	pcrx	Effective Income Tax Rate Reconciliation Foreign EffectiveIncomeTaxRateReconciliationForeign	-0.0115
CY2020	pcrx	Effective Income Tax Rate Reconciliation Foreign Amount EffectiveIncomeTaxRateReconciliationForeignAmount	639000	usd
CY2020	pcrx	Effective Income Tax Rate Reconciliation Foreign EffectiveIncomeTaxRateReconciliationForeign	0.0318
CY2022	pcrx	Effective Income Tax Rate Reconciliation Executive Compensation Amount EffectiveIncomeTaxRateReconciliationExecutiveCompensationAmount	1267000	usd
CY2022	pcrx	Effective Income Tax Rate Reconciliation Executive Compensation Percent EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent	0.0953
CY2021	pcrx	Effective Income Tax Rate Reconciliation Executive Compensation Amount EffectiveIncomeTaxRateReconciliationExecutiveCompensationAmount	719000	usd
CY2021	pcrx	Effective Income Tax Rate Reconciliation Executive Compensation Percent EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent	0.0127
CY2020	pcrx	Effective Income Tax Rate Reconciliation Executive Compensation Amount EffectiveIncomeTaxRateReconciliationExecutiveCompensationAmount	765000	usd
CY2020	pcrx	Effective Income Tax Rate Reconciliation Executive Compensation Percent EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent	0.0381
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2871000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.2158
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	3695000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.0655
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-130150000	usd
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-6.4787
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-1795000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.1349
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-2144000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.0380
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-216000	usd
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.0108
CY2022	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	2542000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.1911
CY2021	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	1690000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.0300
CY2020	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	1591000	usd
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.0792
CY2022	pcrx	Effective Income Tax Rate Reconciliation Interest Expense Amount EffectiveIncomeTaxRateReconciliationInterestExpenseAmount	-3477000	usd
CY2022	pcrx	Effective Income Tax Rate Reconciliation Interest Expense Percent EffectiveIncomeTaxRateReconciliationInterestExpensePercent	-0.2614
CY2021	pcrx	Effective Income Tax Rate Reconciliation Interest Expense Amount EffectiveIncomeTaxRateReconciliationInterestExpenseAmount	0	usd
CY2021	pcrx	Effective Income Tax Rate Reconciliation Interest Expense Percent EffectiveIncomeTaxRateReconciliationInterestExpensePercent	0
CY2020	pcrx	Effective Income Tax Rate Reconciliation Interest Expense Amount EffectiveIncomeTaxRateReconciliationInterestExpenseAmount	0	usd
CY2020	pcrx	Effective Income Tax Rate Reconciliation Interest Expense Percent EffectiveIncomeTaxRateReconciliationInterestExpensePercent	0
CY2022	pcrx	Effective Income Tax Rate Reconciliation Contingent Consideration Amount EffectiveIncomeTaxRateReconciliationContingentConsiderationAmount	-3841000	usd
CY2022	pcrx	Effective Income Tax Rate Reconciliation Contingent Consideration Percent EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent	-0.2888
CY2021	pcrx	Effective Income Tax Rate Reconciliation Contingent Consideration Amount EffectiveIncomeTaxRateReconciliationContingentConsiderationAmount	247000	usd
CY2021	pcrx	Effective Income Tax Rate Reconciliation Contingent Consideration Percent EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent	0.0044
CY2020	pcrx	Effective Income Tax Rate Reconciliation Contingent Consideration Amount EffectiveIncomeTaxRateReconciliationContingentConsiderationAmount	0	usd
CY2020	pcrx	Effective Income Tax Rate Reconciliation Contingent Consideration Percent EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent	0
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	1164000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0875
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	1929000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0342
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	149000	usd
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0074
CY2022	pcrx	Effective Income Tax Rate Reconciliation Tax Reserves Amount EffectiveIncomeTaxRateReconciliationTaxReservesAmount	984000	usd
CY2022	pcrx	Effective Income Tax Rate Reconciliation Tax Reserves Percent EffectiveIncomeTaxRateReconciliationTaxReservesPercent	0.0740
CY2021	pcrx	Effective Income Tax Rate Reconciliation Tax Reserves Amount EffectiveIncomeTaxRateReconciliationTaxReservesAmount	-738000	usd
CY2021	pcrx	Effective Income Tax Rate Reconciliation Tax Reserves Percent EffectiveIncomeTaxRateReconciliationTaxReservesPercent	-0.0131
CY2020	pcrx	Effective Income Tax Rate Reconciliation Tax Reserves Amount EffectiveIncomeTaxRateReconciliationTaxReservesAmount	1539000	usd
CY2020	pcrx	Effective Income Tax Rate Reconciliation Tax Reserves Percent EffectiveIncomeTaxRateReconciliationTaxReservesPercent	0.0766
CY2022	pcrx	Effective Income Tax Rate Reconciliation Convertible Debt Amount EffectiveIncomeTaxRateReconciliationConvertibleDebtAmount	0	usd
CY2022	pcrx	Effective Income Tax Rate Reconciliation Convertible Debt Percent EffectiveIncomeTaxRateReconciliationConvertibleDebtPercent	0
CY2021	pcrx	Effective Income Tax Rate Reconciliation Convertible Debt Amount EffectiveIncomeTaxRateReconciliationConvertibleDebtAmount	0	usd
CY2021	pcrx	Effective Income Tax Rate Reconciliation Convertible Debt Percent EffectiveIncomeTaxRateReconciliationConvertibleDebtPercent	0
CY2020	pcrx	Effective Income Tax Rate Reconciliation Convertible Debt Amount EffectiveIncomeTaxRateReconciliationConvertibleDebtAmount	-1048000	usd
CY2020	pcrx	Effective Income Tax Rate Reconciliation Convertible Debt Percent EffectiveIncomeTaxRateReconciliationConvertibleDebtPercent	-0.0522
CY2022	pcrx	Effective Income Tax Rate Reconciliation Other Reconciling Items EffectiveIncomeTaxRateReconciliationOtherReconcilingItems	169000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.0127
CY2021	pcrx	Effective Income Tax Rate Reconciliation Other Reconciling Items EffectiveIncomeTaxRateReconciliationOtherReconcilingItems	-942000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.0167
CY2020	pcrx	Effective Income Tax Rate Reconciliation Other Reconciling Items EffectiveIncomeTaxRateReconciliationOtherReconcilingItems	-372000	usd
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.0184
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2607000	usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.1960
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	14424000	usd
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.2557
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-125434000	usd
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-6.2439
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-126600000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	151495000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	174203000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	23098000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	35414000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	19979000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	29691000	usd
CY2022Q4	pcrx	Deferred Tax Assets Stock Based Compensation DeferredTaxAssetsStockBasedCompensation	27473000	usd
CY2021Q4	pcrx	Deferred Tax Assets Stock Based Compensation DeferredTaxAssetsStockBasedCompensation	24545000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	2430000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	4889000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	572000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	11036000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2441000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	237970000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	269296000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	54743000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	81418000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Financing Arrangements DeferredTaxLiabilitiesFinancingArrangements	-13000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Financing Arrangements DeferredTaxLiabilitiesFinancingArrangements	15521000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	54730000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	96939000	usd
CY2022Q4	pcrx	Deferred Tax Assets Gross Netof Deferred Tax Liabilities Before Valuation Allowance DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance	183240000	usd
CY2021Q4	pcrx	Deferred Tax Assets Gross Netof Deferred Tax Liabilities Before Valuation Allowance DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance	172357000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	22931000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18993000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	160309000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	153364000	usd
CY2022	pcrx	Minimum Cumulative Percentage Of Change In Ownership As Condition To Offset Taxable Income Or Tax MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax	0.50
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	3900000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	16500000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	2700000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	200000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	800000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6300000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6076000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	1355000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	4300000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9021000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	3526000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	827000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6322000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3400000	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2800000	usd
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2900000	usd
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	300000	usd
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	200000	usd
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	200000	usd
CY2022	pcrx	Share Based Compensation Arrangement By Share Based Payment Award Performance Period ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod	P1Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P3Y
CY2022Q4	us-gaap	Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent	1000000	usd
CY2021Q4	us-gaap	Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent	1200000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P3Y
CY2022Q4	us-gaap	Deferred Compensation Cashbased Arrangements Liability Classified Noncurrent DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent	2200000	usd
CY2021Q4	us-gaap	Deferred Compensation Cashbased Arrangements Liability Classified Noncurrent DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent	1200000	usd
CY2022	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	4494000	usd
CY2021	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	26371000	usd
CY2020	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	0	usd
CY2022	pcrx	Business Combination Acquisition And Integration Related Costs BusinessCombinationAcquisitionAndIntegrationRelatedCosts	11245000	usd
CY2021	pcrx	Business Combination Acquisition And Integration Related Costs BusinessCombinationAcquisitionAndIntegrationRelatedCosts	40900000	usd
CY2020	pcrx	Business Combination Acquisition And Integration Related Costs BusinessCombinationAcquisitionAndIntegrationRelatedCosts	150000	usd
CY2022	pcrx	Acquisition Related Charges Impairment And Other AcquisitionRelatedChargesImpairmentAndOther	10903000	usd
CY2021	pcrx	Acquisition Related Charges Impairment And Other AcquisitionRelatedChargesImpairmentAndOther	42911000	usd
CY2020	pcrx	Acquisition Related Charges Impairment And Other AcquisitionRelatedChargesImpairmentAndOther	5166000	usd
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	5200000	usd
CY2022	pcrx	Impairment Of Intangible Assets Carrying Value ImpairmentOfIntangibleAssetsCarryingValue	60000000	usd
CY2022	pcrx	Impairment Of Intangible Assets Fair Value ImpairmentOfIntangibleAssetsFairValue	33900000	usd

Files In Submission

Name	View Source	Status
0001396814-23-000010-index-headers.html	Edgar Link	pending
0001396814-23-000010-index.html	Edgar Link	pending
0001396814-23-000010.txt	Edgar Link	pending
0001396814-23-000010-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pcrx-12312022xex1025.htm	Edgar Link	pending
pcrx-12312022xex211.htm	Edgar Link	pending
pcrx-12312022xex231.htm	Edgar Link	pending
pcrx-12312022xex311.htm	Edgar Link	pending
pcrx-12312022xex312.htm	Edgar Link	pending
pcrx-12312022xex321.htm	Edgar Link	pending
pcrx-20221231.htm	Edgar Link	pending
pcrx-20221231.xsd	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
pcrx-20221231_g1.jpg	Edgar Link	pending
pcrx-20221231_g2.jpg	Edgar Link	pending
pcrx-20221231_g3.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
pcrx-20221231_def.xml	Edgar Link	unprocessable
pcrx-20221231_lab.xml	Edgar Link	unprocessable
pcrx-20221231_pre.xml	Edgar Link	unprocessable
pcrx-20221231_htm.xml	Edgar Link	completed
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
pcrx-20221231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PCRX
Pacira Biosciences Inc Stock $pcrx

2023 Q1 Form 10-K Financial Statement

#000139681423000010 Filed on February 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCRX Pacira Biosciences Inc Stock $pcrx

2023 Q1 Form 10-K Financial Statement

#000139681423000010 Filed on February 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCRX
Pacira Biosciences Inc Stock $pcrx